New drug combo aims to control Hard-to-Treat multiple myeloma
NCT ID NCT07312188
First seen Jan 07, 2026 · Last updated May 24, 2026 · Updated 19 times
Summary
This study tests a new drug called F182112 given with different treatment plans for people whose multiple myeloma has come back or stopped responding to prior therapies. About 90 participants will receive the drug combination to see if it can shrink tumors and delay cancer growth. The goal is to find a better way to manage this advanced blood cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
Conditions
Explore the condition pages connected to this study.